comparemela.com

Latest Breaking News On - Stoke therapeutics daily - Page 7 : comparemela.com

Needham & Company LLC Trims Stoke Therapeutics (NASDAQ:STOK) Target Price to $14 00

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) had its price target dropped by stock analysts at Needham & Company LLC from $25.00 to $14.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 188.66% […]

Brokerages Set Stoke Therapeutics, Inc (NASDAQ:STOK) Target Price at $23 50

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among […]

Stoke Therapeutics, Inc (NASDAQ:STOK) Receives Consensus Recommendation of Moderate Buy from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month […]

Stoke Therapeutics (NASDAQ:STOK) Given New $14 00 Price Target at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOK) Given New $14 00 Price Target at Cantor Fitzgerald
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $14 00 at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOK – Free Report) had its target price decreased by Cantor Fitzgerald from $18.00 to $14.00 in a research note released on Tuesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2023 earnings at ($2.42) EPS and FY2024 earnings at […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.